https://pharminent.com/oncology/oncology-intelligence-digest-may-22-2026/ 2026-05-23T01:02:30Z Pharminent en Oncology Intelligence Digest • May 22, 2026 2026-05-23T01:02:27Z Blog https://pharminent.com/81009-2/ 2026-05-23T00:54:18Z Pharminent en 2026-05-23T00:54:12Z Blog https://pharminent.com/market-access/market-access-intelligence-weekly-digest-may-22-2026/ 2026-05-22T19:57:31Z Pharminent en MARKET ACCESS INTELLIGENCE • Weekly Digest • May 22, 2026 2026-05-22T19:57:29Z Blog https://pharminent.com/glp-1-competitive-market/glp-1-competitive-market-digest-weekly-may-22-2026/ 2026-05-22T19:52:35Z Pharminent en GLP-1 Competitive Market Digest • Weekly • May 22, 2026 2026-05-22T19:52:33Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-may-22-2026/ 2026-05-22T17:30:34Z Pharminent en Strategic News Watch • May 22, 2026 2026-05-22T17:30:32Z Blog https://pharminent.com/parkinsons-drug-from-biogen-denali-comes-up-short/ 2026-05-22T16:17:05Z Pharminent en Parkinson's drug from Biogen, Denali comes up short 2026-05-22T14:46:00Z Blog https://pharminent.com/kelun-merck-validate-trop2-keytruda-pairing-in-lung-cancer-with-improved-survival/ 2026-05-22T16:17:07Z Pharminent en Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival 2026-05-22T14:04:07Z Blog https://pharminent.com/gilead-inks-140m-api-supply-deal-tightening-ties-to-korean-manufacturer/ 2026-05-22T16:17:08Z Pharminent en Gilead inks $140M API supply deal, tightening ties to Korean manufacturer 2026-05-22T12:09:36Z Blog https://pharminent.com/gbl-joins-cvc-in-10-7bn-takeover-bid-for-recordati/ 2026-05-22T16:17:09Z Pharminent en GBL joins CVC in 10.7bn takeover bid for Recordati 2026-05-22T10:37:57Z Blog https://pharminent.com/gilead-sciences-completes-tubulis-acquisition-for-5bn/ 2026-05-22T16:17:09Z Pharminent en Gilead Sciences completes Tubulis acquisition for $5bn 2026-05-22T10:19:52Z Blog https://pharminent.com/80959-2/ 2026-05-21T23:31:34Z Pharminent en 2026-05-21T23:31:31Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-may-21-2026/ 2026-05-21T23:27:31Z Pharminent en Rare Disease & Gene Therapy Digest • May 21, 2026 2026-05-21T23:27:29Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-may-21-2026/ 2026-05-21T17:11:21Z Pharminent en Strategic News Watch • May 21, 2026 2026-05-21T17:10:24Z Blog https://pharminent.com/in-alzheimers-bristol-myers-sees-big-promise-beyond-amyloid/ 2026-05-21T15:49:10Z Pharminent en In Alzheimer's, Bristol Myers sees big promise beyond amyloid 2026-05-21T13:00:00Z Blog https://pharminent.com/lillys-triple-agonist-shows-bariatric-surgery-like-weight-loss-results/ 2026-05-21T15:49:43Z Pharminent en Lilly's triple agonist shows bariatric surgery-like weight loss results 2026-05-21T12:55:42Z Blog https://pharminent.com/lillys-triple-g-retatrutide-aces-crucial-obesity-trial/ 2026-05-21T23:22:52Z Pharminent en Lilly's 'triple G' retatrutide aces crucial obesity trial 2026-05-21T12:14:28Z Blog https://pharminent.com/lilly-bms-incyte-strike-deals-to-keep-biopharmas-ai-integration-rolling/ 2026-05-21T15:49:54Z Pharminent en Lilly, BMS, Incyte strike deals to keep biopharma's AI integration rolling 2026-05-21T11:29:44Z Blog https://pharminent.com/biomarin-bounces-back-as-voxzogo-performs-bigger-than-expected-in-new-indication/ 2026-05-21T19:25:52Z Pharminent en BioMarin bounces back as Voxzogo performs 'bigger than expected' in new indication 2026-05-21T11:19:14Z Blog https://pharminent.com/eli-lilly-maintains-ma-streak-with-202m-engage-bio-buyout/ 2026-05-21T15:50:05Z Pharminent en Eli Lilly maintains M&A streak with $202m Engage Bio buyout 2026-05-21T10:22:38Z Blog https://pharminent.com/fujifilm-opens-new-ipsc-facility-in-madison-us-2/ 2026-05-21T23:22:54Z Pharminent en FUJIFILM opens new iPSC facility in Madison, US 2026-05-21T10:04:15Z Blog https://pharminent.com/bayer-gets-swift-review-for-kerendia-in-type-1-diabetes/ 2026-05-21T15:50:14Z Pharminent en Bayer gets swift review for Kerendia in type 1 diabetes 2026-05-21T09:41:08Z Blog https://pharminent.com/ats-2026-pabpc4-gene-identified-as-a-key-driver-of-emphysema-in-copd/ 2026-05-21T19:25:54Z Pharminent en ATS 2026: PABPC4 gene identified as a key driver of emphysema in COPD 2026-05-21T09:34:40Z Blog https://pharminent.com/ats-2026-long-term-data-show-durable-benefit-of-trikafta-for-cystic-fibrosis/ 2026-05-21T15:50:35Z Pharminent en ATS 2026: Long-term data show durable benefit of Trikafta for cystic fibrosis 2026-05-21T09:30:18Z Blog